Development of VISTA in tumor immunotherapy
10.11665/j.issn.1000-5048.20220403
- VernacularTitle:VISTA靶点肿瘤免疫治疗的研究进展
- Author:
Yu ZHANG
1
;
Fang YAN
;
Yibei XIAO
Author Information
1. 中国药科大学药学院
- Publication Type:Journal Article
- Keywords:
checkpoint;
VISTA;
immuno-checkpoint inhibitors (ICIs);
tumor immunity;
advances
- From:
Journal of China Pharmaceutical University
2022;53(4):400-409
- CountryChina
- Language:Chinese
-
Abstract:
V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a member of the B7 family that maintains homeostasis in T cells and myeloid cells.Blocking VISTA inhibits tumor development in in vitro and in vivo trials, and is an important target for tumor immunotherapy.This review focuses on its structural features, expression and biological functions in tumor microenvironment, summarizes the current stage of small molecule inhibitors and antibodies targeting VISTA, and discusses the research approaches.It aims to provide a rationale for subsequent study on VISTA and the development of related immune checkpoint antitumor drugs.
